OBI Pharma Inc (台灣浩鼎) shares yesterday fell by more than 4 percent, worse than the 0.95 percent decline on the over-the-counter market, as investors reacted negatively to new allegations about a conflict of interest in the company’s shareholding.
The stock closed at NT$415.50 on the Taipei Exchange, down from the previous day’s NT$433. Since the beginning of this year, the drug developer’s shares have dropped 36.56 percent, while the TPEX has increased 1.48 percent over the same period.
The Chinese-language Next Magazine yesterday reported that the daughter of Academia Sinica President Wong Chi-huey (翁啟惠) bought about 3 million shares of OBI Pharma in 2012.
The report said that Wong Yu-shioh (翁郁琇) bought the OBI shares at a relatively low price of NT$31 per share, potentially allowing her to reap billions of New Taiwan dollars in profit.
Academia Sinica, the nation’s leading research academy, works in close collaboration with OBI Pharma. When the company last month released discouraging results on the second and third-phase clinical trials of a new breast cancer drug, OBI-822, Wong Chi-huey voiced his support for the drug, saying that the flawed design of the clinical trial was to blame for the failure.
As a close collaborator of the company and a government official, Wong Chi-huey’s positive comments about OBI-822 have raised eyebrows.
At the legislature’s Finance Committee meeting yesterday, Chinese Nationalist Party (KMT) Legislator-at-large William Tseng (曾銘宗) raised the issue and demanded that the financial regulator take action on the matter.
“If his daughter is confirmed to have received the 3 million shares from Ruentex Group (潤泰集團), Wong Chi-huey cannot just walk away,” Tseng said, referring to the magazine report.
Ruentex Group is one of OBI Pharma’s major shareholders.
According to the latest data from the Taiwan Stock Exchange, as of June 24, 2014, Wong Yu-shioh held 1.93 million shares, or 1.29 percent, of OBI Pharma stock.
Earlier this month, Tseng urged the Financial Supervisory Commission to determine if Wong Chi-huey had violated the Securities and Exchange Act (證券交易法) by speaking on behalf of OBI Pharma.
Financial Supervisory Commission Chairwoman Jennifer Wang (王儷玲) told the committee meeting that based on an internal investigation, the commission had found that there were concerns over the matter.
“We have forwarded all related materials in our hands to prosecutors for further investigation,” Wang said.
OBI Pharma chairman Michael Chang (張念慈) later in the day issued a statement saying that information about all major shareholders were already made public before the company started trading on the smaller Emerging Stock Market in 2012.
In the statement, Chang said that Wong Yu-shioh was one of the major shareholders of US-based Optimer Pharmaceuticals Inc, the parent company of OBI Pharma at the time, and she bought the shares before its Emerging Stock Market debut in 2012.
Chang also voiced his support for Wong Chi-huey, saying that previous remarks made by the scientist should not be taken as signs of stock market manipulation.
Chinese-language monthly Wealth Magazine executive director Hsieh Chin-ho (謝金河) yesterday questioned Wong Chi-huey’s role in the company.
“Some people might find president Wong being so positive [on the company] is likely due to the massive interests behind,” Hsieh wrote on Facebook.
Media personality Clara Chou (周玉蔻) said that the ongoing affair is destroying Wong’s reputation and would further harm the prospects of Taiwan’s biotech industry.
‘BIG LOSS’: This year might see the last generation of Huawei’s Kirin chips, as their production would stop next month because they are made using US technology Chinese tech giant Huawei Technologies Co (華為) is running out of processor chips to make smartphones due to US sanctions and would be forced to stop production of its own most advanced chips, a company executive has said, in a sign of growing damage to Huawei’s business from US pressure. Huawei, one of the biggest producers of smartphones and network equipment, is at the center of US-Chinese tension over technology and security. Washington last year cut off Huawei’s access to US components and technology, and those penalties were tightened in May, when the White House barred vendors worldwide from using US
’WHITE BOX’: The open platform would give local firms access to Cisco’s cloud-based mobile network to develop 5G telecom equipment and tap into the global market The Ministry of Economic Affairs (MOEA) yesterday introduced a new 5G “open lab” in collaboration with US-based information technology and networking giant Cisco Systems Inc to address the rapidly growing “white box” 5G networking equipment market. The open lab will be a platform where Taiwanese manufacturers can access Cisco’s cloud-based mobile network to develop their own 5G telecom equipment, such as small-cell base stations, network switches, modems and Internet of things (IoT) devices, a ministry statement said. The open platform would allow Taiwanese manufacturers to tap into the lucrative 5G telecom equipment market, which was previously monopolized by Nokia Oyj, Ericsson AB
CORPORATE SCANDAL: Cathay Life has invested NT$13.3 billion in Bank Mayapada since 2015, but the latest loss of NT$8.8 billion has completely written off its investment Cathay Life Insurance Co (國泰人壽) yesterday said it would recognize an investment loss of NT$8.8 billion (US$298.1 million) in Indonesia’s Bank Mayapada Internasional Tbk PT due to concerns about the lender’s operations amid a corporate scandal. The company said it would revise its earnings result for June, from a net profit of NT$6.52 billion to a net loss of NT$520 million, its first monthly loss over the past 17 months. After booking an investment loss of NT$5.2 billion in Bank Mayapada earlier this year, Cathay Life has so far recognized total investment losses of NT$14 billion in the lender, executive vice president
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday reported that revenue last month expanded 25 percent annually, but fell 12.8 percent month-on-month to NT$105.96 billion (US$3.59 billion). In the first seven months of this year, the chipmaker’s revenue surged 33.6 percent to NT$727.26 billion, compared with NT$544.46 billion a year earlier. TSMC has said it aims to grow its revenue by more than 20 percent this year. The company has since May 15 stopped taking new orders from Huawei Technologies Co (華為), its second-biggest customer after Apple Inc, due to the US’ restrictions on exports containing US technologies. TSMC has no plans to